Amicus Therapeutics Inc. (FOLD) Insider Hung Do Sells 25,000 Shares
Amicus Therapeutics Inc. (NASDAQ:FOLD) insider Hung Do sold 25,000 shares of Amicus Therapeutics stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $7.25, for a total value of $181,250.00. Following the transaction, the insider now directly owns 558,453 shares of the company’s stock, valued at $4,048,784.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Hung Do also recently made the following trade(s):
- On Tuesday, September 6th, Hung Do sold 25,000 shares of Amicus Therapeutics stock. The stock was sold at an average price of $7.00, for a total value of $175,000.00.
Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) opened at 7.51 on Thursday. The stock’s market cap is $1.07 billion. The stock has a 50 day moving average price of $7.19 and a 200-day moving average price of $6.95. Amicus Therapeutics Inc. has a 12 month low of $4.98 and a 12 month high of $11.78.
Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by $0.07. On average, analysts forecast that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target for the company in a research report on Monday, July 25th. Chardan Capital set a $15.00 price target on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Finally, Leerink Swann reissued an “outperform” rating and set a $19.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Tuesday, June 14th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $12.19.
A number of large investors have recently added to or reduced their stakes in FOLD. Schwab Charles Investment Management Inc. increased its stake in Amicus Therapeutics by 11.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 459,801 shares of the biopharmaceutical company’s stock worth $2,511,000 after buying an additional 48,690 shares during the period. Redmile Group LLC increased its stake in Amicus Therapeutics by 3.6% in the second quarter. Redmile Group LLC now owns 11,106,446 shares of the biopharmaceutical company’s stock worth $60,641,000 after buying an additional 388,026 shares during the period. Palo Alto Investors LLC increased its stake in Amicus Therapeutics by 12.9% in the second quarter. Palo Alto Investors LLC now owns 4,009,375 shares of the biopharmaceutical company’s stock worth $21,891,000 after buying an additional 458,202 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in Amicus Therapeutics by 14.6% in the second quarter. Metropolitan Life Insurance Co. NY now owns 92,989 shares of the biopharmaceutical company’s stock worth $508,000 after buying an additional 11,881 shares during the period. Finally, Numeric Investors LLC purchased a new stake in Amicus Therapeutics during the second quarter worth $414,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).
Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.